Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016053 (fibromyalgia)
 4,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty-four female patients who met the following criteria were studied. All were referred for rheumatology consultation because of symptoms and a positive antinuclear antibody (ANA) to rule out lupus. None fulfilled the American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) at the time of the initial visit. All had a normal or noncontributory complete blood count, urinalysis, and blood panel. They lacked antideoxyribonucleic acid, anti-Smith (anti-Sm), antiribonucleoprotein (anti-RNP), anti-Ro, anti-La, and antiscleroderma 70 (anti-Scl-70) antibodies, and none had rheumatoid factor, elevated creatine phosphokinase levels, or decreased C3 complement or C4 complement values. We performed additional tests or procedures in an effort to improve diagnostic accuracy. Nine of 44 (20%) had a negative ANA on retesting. All patients were tested for antiribosomal P, antineuronal, antihistone-(H2A-H2B)/deoxyribonucleic acid complex antibody, anti-smooth muscle antibody and antithyroid antibodies, as well as Westergren sedimentation rate. Anticardiolipin antibody, serum protein electrophoresis, bone scanning, or skin biopsies with or without lupus band testing were obtained as clinically indicated. At the 6-month follow-up, 19 patients (43%) fulfilled the ACR criteria for SLE, 14 (32%) fulfilled the ACR criteria for fibromyalgia only, 4 (9%) had seronegative rheumatoid arthritis, 1 (2%) had myasthenia gravis, and 6 (14%) remained undiagnosed; 18/19 diagnosed with SLE had an additional antibody or positive diagnostic test listed above versus 3/25 without SLE (p<0.0001). Additional laboratory and diagnostic testing beyond the routine ANA profile correlated with the evolving diagnosis in 86% of the patients at 6 months.
 ...
PMID:The 'rule out lupus' rheumatology consultation: clinical outcomes and perspectives. 1907 69

In amyotrophic lateral sclerosis (ALS), a recent double-blind placebo-controlled trial of acetyl-L-carnitine along with riluzole showed probable benefit in 42 patients compared with 40 patients who received placebo. Using an electrophysiologic measure devised to differentiate ALS from other neuromuscular conditions, a "splint-hand index" was devised and is reviewed. Analysis of skin in ALS may also be of interest, and there was a report of accumulation of fused in sarcoma protein in the epidermis of ALS patients. With regard to myasthenia gravis, there is another report that early treatment of ocular symptoms with corticosteroids may prevent the development of generalized symptoms. A new study of thymus histopathology in muscle-specific tyrosine kinase (MuSK) myasthenia gravis is covered and another article on the use of thymectomy. In Duchenne muscular dystrophy, the best method of administrating corticosteroids is still being debated, and a long-term study of daily versus intermittent prednisolone is reviewed. The study showed less sustained benefit from the intermittent prednisolone but with a better side effect profile. According to 2 recent reports, it seems that titin mutations may be an underrecognized cause of myopathy with early respiratory failure in adults. Keeping with the respiratory failure theme, there was also an interesting article on the long-term benefits and side effects of cyclosporine in patients with interstitial lung disease from antisynthetase syndrome. Finally, the spectrum of small fiber neuropathy may be expanding to include a causative role in some patients with fibromyalgia syndrome and in juveniles with diffuse pain and a possible autoimmune predisposition.
...
PMID:What's in the literature? 2396 8

Microfluidic devices have advanced significantly in recent years and are a promising technology for the field of tissue engineering. Highly sophisticated microfabrication techniques have paved the way for the development of complex ex vivo models capable of incorporating and measuring the real-time response of multiple cell types interacting together in a single system. Muscle-on-a-chip technology has drastically improved and serves as a drug screening platform for many muscular diseases such as muscular dystrophy, tendinosis, fibromyalgia, mitochondrial myopathy, and myasthenia gravis. This review seeks to communicate the gaps in knowledge of current muscular disease models and highlight the power of microfluidic devices in enabling researchers to better understand disease pathology and provide high throughput screening of therapeutics for muscular myopathies.
 ...
PMID:Microfluidic devices for disease modeling in muscle tissue. 3019 8